Regeneus to receive cash payment for trial success

Regeneus (ASX:RGS) is set to receive a milestone payment of US$1 million for meeting the primary endpoints of its Phase 1 safety trial of Progenza in patients with knee osteoarthritis.

Progenza is Regeneus’s flagship asset, and is a patented off-the-shelf stem cell technology developed for the treatment of knee osteoarthritis and other inflammatory conditions.

Read more

Amazon buys Whole Foods(!) for $13.7 billion

Amazon has acquired Whole Foods, a move that marks the ecommerce giant’s official entry into the world of brick-and-mortar stores as well as groceries.

It’s Amazon’s biggest acquisition ever—and it’s not even close. The company is paying $13.7 billion in cash for the grocery chain, which now operates some 465 stores across the U.S.

Read more

Private equity, capital flows bolster local 2017 M&A prospects

Local bankers and lawyers expect a strong final half for mergers and acquisitions, after a jump in activity and resurgence in private equity-led deals so far this year.

Those canvassed by The Australian Financial Review said the pipeline of M&A deals was healthy, and buoyed by large pools of global capital that had to be deployed and favourable funding markets. They expect a strong rather than stellar finish to 2017.

Read more

The week in medical cannabis: ethics approval granted, new JV formed

It’s been a big week for Australia’s growing medical cannabis industry, with ethics approval granted for two human trials as well as the formation of a new joint venture.

Life science company Medlab Clinical Limited has received Human Research Ethics Committee (HREC) approvals to begin human trials of two different cannabis-based medicines. Developed at Medlab’s Sydney laboratory, the patent-pending medicines have two different applications and will be clinically tested at different locations.

Read more

Bioshares analysis: 60 of 101 biotech firms lifted market cap in 3 years, as Oventus reaches distribution deal

BIOTECHNOLOGY can be risky, but a new study shows that almost 60 per cent of life-science companies have grown in stockmarket size over the past three years.

At least 25 out of 101 surveyed companies had doubled their market capitalisation, the study by sector analysts Bioshares found. Fifteen of the 101 companies listed since June 2015 had at least tripled.

Read more

Precision gene editing may deliver biofuel promise

For decades now, we’ve been promised cheap biofuels from algae. But there’s no free lunch. Growing these mini oil factories in vast ponds requires fertiliser and mechanical aeration; and then the oil has to be extracted. It all costs energy and money so the yields need to be high to make it worthwhile.

One promising industrial species is Nannocholoropsis gaditana, which can produce a lipid – the oil and fat energy store – content up to about 60% of the algae’s ash-free dry weight. But Eric Moellering and colleagues at the company Synthetic Genomics Inc in California, wanted to do better.

Read more

argenx receives second preclinical milestone payment in collaboration with LEO Pharma

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the achievement of the second of two preclinical milestones in connection with its collaboration with LEO Pharma.”Our collaboration with LEO Pharma continues to be highly productive with the announcement of this most recent preclinical milestone. This achievement is the second of two success-based preclinical milestones with the first having been received last year.

Brisbane to host major life sciences industry conference in 2018

SAN DIEGO, USA: International bio investors have been invited to Brisbane after Premier Annastacia Palaszczuk announced the Queensland capital will play host next year to a gathering of the leading players in one of Australia’s most exciting and promising high-tech industries.

Speaking at the BIO International Convention in San Diego in the United States, Ms Palaszczuk said almost 1000 business leaders, investors and scientists from Australia and overseas would attend the AusBiotech 2018 national conference from 31 October to 2 November at the Brisbane Convention and Exhibition Centre next year.

Read more

We Are One Step Closer To Large-Scale Algae-Based Biofuel

Making biofuel from algae has just got a little bit easier, as a newly engineered strain produces twice as much oil as its wild parent, according to Californian researchers.

Previous attempts to get this type of algae to make more oil crippled its growth, which isn’t an issue with this new strain. Without the growth restrictions, we are now one step closer to producing biodiesel on a large scale, say the researchers.

Read more